A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities – Erratum

Valentine Grumberg; Stéphane Roze; Julie Chevalier; John Borrill; Anne-Françoise Gaudin; Sébastien Branchoux

doi:10.1017/S0266462322000228

A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities – Erratum

Published online by Cambridge University Press: 17 May 2022

Anne-Françoise Gaudin and

Sébastien Branchoux

Article contents

Abstract
References

Rights & Permissions

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Type: Correction
Information: International Journal of Technology Assessment in Health Care , Volume 38 , Issue 1 , 2022 , e38

DOI: https://doi.org/10.1017/S0266462322000228 [Opens in a new window]
Creative Commons: This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright: © The Author(s), 2022. Published by Cambridge University Press

In the original publication of Grumberg et al. (Reference Grumberg, Roze, Chevalier, Borrill, Gaudin and Branchoux2022) a typesetting error occurred in Table 2. The correct Table 2 is reproduced below.

Table 2. Best-Fit and Second Best-Fit Models to OS Kaplan–Meier Curves with at least 18-Month Extended Follow-up

Abbreviations: HR: hazard ratio; KM: Kaplan-Meier; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; RMST: restricted mean survival time; UC: urothelial cancer.

The publisher apologizes for this error.

References

Grumberg, V., Roze, S., Chevalier, J., Borrill, J., Gaudin, A., & Branchoux, S. (2022). A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. International Journal of Technology Assessment in Health Care, 38(1), E28. doi:10.1017/S0266462322000125CrossRef Google Scholar PubMed